$CRL

Knell Michael Gunnar sold $1.7M of CRL

Knell Michael Gunnar (SVP, Finance and CAO) sold 6,645 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at an average of $260.38 ($258.53–$265.17, $1.73M total) across 9 trades on 2026-08-06.

Original reporting
SEC EDGAR · Knell Michael Gunnar
Published Aug 10, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRL
Neutral
medium confidence
Mentioned
$CRL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

It provides a fresh, primary-source datapoint on insider selling size, timing, and average price range, but it does not include any new business, earnings, or regulatory information.

02

Market read

Traders may monitor insider activity as a sentiment input, but this specific filing lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is indicated, so traders may over-interpret intent; also, the sales occurred Aug. 6, so the market impact may already be partially priced.

Relevance 6/10Novelty 4/10Timing: Form 4 filed Aug. 10, covering sales executed Aug. 6

Background

The article is an SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc.

Company-level read

Ticker impact

$CRLNeutralMedium confidence
Context

Charles River Laboratories insider Knell sold about $1.73M of CRL shares in an open-market sale reported on Form 4 filed Aug. 10.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

This is a routine Form 4 insider transaction with no 10b5-1 plan stated and no accompanying operational or guidance change disclosed in the text.

Market effects

Minimal, as the disclosure is company-specific insider selling without sector-wide regulatory or clinical signals.

None indicated.

None indicated.

Counterpoint

The sale may be driven by personal liquidity needs rather than a negative view, especially since the filing does not provide a fundamental rationale.

Key entities

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

    CRL, the company whose insider transaction is disclosed.

  • Knell Michael Gunnar

    SVP, Finance and CAO who sold 6,645 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.